---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-008865"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:52:09.827308+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock reports positive SRK-181 Phase 1 data across multiple tumors; ccRCC ORR 23.3%

## Summary
- SRK-181 + pembrolizumab showed ORR 23.3% in ccRCC, 27.3% in melanoma, 18.2% in HNSCC, 9.1% in UC; no NSCLC response.
- Safety manageable: no Grade 5 AEs; most common AEs were rash, pruritus, fatigue; one Grade 4 dermatitis exfoliative.
- Biomarker analysis in ccRCC: baseline CD8+ infiltration doubled ORR to 40%; elevated Treg levels raised ORR to 50%.
- Company plans end of Phase 1 meeting with FDA and evaluating partnership opportunities for SRK-181.

## SEC filing metadata
- accession: 0001558370-24-008865
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000155837024008865/0001558370-24-008865-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000155837024008865/srrk-20240603x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-008865
- JSON: https://secwatch.observer/filing/0001558370-24-008865.json
- Plain text: https://secwatch.observer/filing/0001558370-24-008865.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.